



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Lianhmingthangi, Assistant Drugs Inspector (F and D)
CMO Office
Siaha District, Mizoram- 796901
2. Serial No. and date of Inspector's memorandum : SD/19/037N-DRUGS , 24-MAR-2025
3. Number of Sample : NIL
4. Date of receipt : 04-APR-2025
5. Names of drugs purporting to be contained in the sample : Cefixime Dispersible Tablets IP (Cefime O 200 Tablets)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0448	GUW/LS/2025-26/452	SPT-36406	Sep-2023 Aug-2025	NA	Shervotec Pharmaceuticals, Plot No 82/4 & 82/5, HPSIDC Baddi, Distt. Solan (H.P.) -173205

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 27-May-2025 To 01-Jul-2025

COMPOSITION : Each uncoated dispersible tablet contains:
Cefixime Trihydrate I.P. eq. to Cefixime (Anhydrous) 200 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Light orange colored, round shaped, bi-convex, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Cefixime Trihydrate.	NA
3	Average weight	0.3028 g	NA
4	Uniformity of weight	Complies.	+5 % of Average weight
5	Disintegration	Complies. (Time taken for disintegration 32 seconds)	NMT 3 minutes

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

1	Cefixime Trihydrate Eq to Cefixime anhydrous	197.44 mg/Tablet	200 mg/Tablet	98.72	90 % to 110 %	I.P. 2022
---	--	------------------	------------------	-------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 07-JUL-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

